StockData
Anika Therapeutics, Inc. logo

Anika Therapeutics, Inc. (ANIK) stock

ANIKNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/30
$12.92−0.48 (-3.58%)

Close on Nov 16, 2026Market cap $172.91MP/E –Yield –

Anika Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Anika Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -4.2%. For fiscal 2025 it was -9.8%, against -4.3% the year before. The highest annual figure on record is 58.2% in fiscal 2014.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-9.8%−5.5
FY2024Dec 31, 2024-4.3%−5.0
FY2023Dec 31, 20230.7%−2.5
FY2022Dec 31, 20223.2%+1.5
FY2021Dec 31, 20211.8%+23.5
FY2020Dec 31, 2020-21.7%−51.6
FY2019Dec 31, 201929.9%+9.3
FY2018Dec 31, 201820.6%−19.7
FY2017Dec 31, 201740.3%−8.6
FY2016Dec 31, 201649.0%−2.8
FY2015Dec 31, 201551.8%−6.4
FY2014Dec 31, 201458.2%+14.8
FY2013Dec 31, 201343.4%+15.8
FY2012Dec 31, 201227.6%+6.1
FY2011Dec 31, 201121.6%+8.0
FY2010Dec 31, 201013.6%−0.4
FY2009Dec 31, 200913.9%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 20269.1%+23.9
Q1 FY2026Mar 31, 2026-18.5%−2.2
Q4 FY2025Dec 31, 20252.1%+4.4
Q3 FY2025Sep 30, 2025-11.6%−11.3
Q2 FY2025Jun 30, 2025-14.8%−8.9
Q1 FY2025Mar 31, 2025-16.4%−7.7
Q4 FY2024Dec 31, 2024-2.3%−59.8
Q3 FY2024Sep 30, 2024-0.3%+18.2
Q2 FY2024Jun 30, 2024-5.9%+2.3
Q1 FY2024Mar 31, 2024-8.6%+24.5
Q4 FY2023Dec 31, 202357.5%+16.1
Q3 FY2023Sep 30, 2023-18.5%−4.1
Q2 FY2023Jun 30, 2023-8.2%+0.3
Q1 FY2023Mar 31, 2023-33.1%−23.4
Q4 FY2022Dec 31, 202241.4%+66.9
Q3 FY2022Sep 30, 2022-14.4%−17.7
Q2 FY2022Jun 30, 2022-8.5%−32.6
Q1 FY2022Mar 31, 2022-9.7%−13.4
Q4 FY2021Dec 31, 2021-25.5%+29.5
Q3 FY2021Sep 30, 20213.3%+28.3
Q2 FY2021Jun 30, 202124.1%+55.2
Q1 FY2021Mar 31, 20213.7%−16.4
Q4 FY2020Dec 31, 2020-54.9%−71.1
Q3 FY2020Sep 30, 2020-25.0%−65.6
Q2 FY2020Jun 30, 2020-31.1%−70.3
Q1 FY2020Mar 31, 202020.0%−2.1
Q4 FY2019Dec 31, 201916.1%−20.1
Q3 FY2019Sep 30, 201940.6%+8.6
Q2 FY2019Jun 30, 201939.2%+2.4
Q1 FY2019Mar 31, 201922.2%+59.0
Q4 FY2018Dec 31, 201836.2%+3.1
Q3 FY2018Sep 30, 201832.0%−5.8
Q2 FY2018Jun 30, 201836.8%−16.2
Q1 FY2018Mar 31, 2018-36.8%−71.1
Q4 FY2017Dec 31, 201733.1%−11.2
Q3 FY2017Sep 30, 201737.8%−15.3
Q2 FY2017Jun 30, 201753.0%–
Q1 FY2017Mar 31, 201734.2%–
Q4 FY2016Dec 31, 201644.4%–
Q3 FY2016Sep 30, 201653.1%–

More Anika Therapeutics figures

See a number that looks wrong?